hypophosphatemia%20-and-%20hyperphosphatemia
HYPOPHOSPHATEMIA & HYPERPHOSPHATEMIA

Hypophosphatemia is an electrolyte imbalance where there is a decrease in the serum phosphate level that is less than the normal range.

It is recognized most often in critically-ill patients, decompensated diabetics, alcoholics or other malnourished persons, and acute infectious or pulmonary disorders.

It may be transient and reflect intracellular shift with minimal clinical consequences.

Hyperphosphatemia is an electrolyte disturbance in which an increase in the serum phosphate level of more than the normal range is present.

Most symptoms of acute hyperphosphatemia are due to secondary hypocalcemia.

The significant level of hyperphosphatemia in adults is >6 mg/dL.

Hypophosphatemia%20-and-%20hyperphosphatemia Management

Monitoring

Monitoring of Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients
  • Monitoring of serum phosphate in CKD patients should start in patients with grade 3 CKD
    • Frequency of monitoring will be based on the presence and magnitude of abnormalities and the rate of progression of the disease
  • Monitoring of serum phosphate intervals may be as followed:
    • Every 6-12 months in patients with grade 3 CKD
    • Every 3-6 months in patients with grade 4 CKD
    • Every 1-3 months in patients with grade 5 CKD
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
28 Apr 2020
Women who skip breakfast before and during early pregnancy have a higher risk of developing gestational diabetes mellitus (GDM) than those who have the essential meal daily, suggests a study.
Pearl Toh, 23 Sep 2020
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
Roshini Claire Anthony, 23 Sep 2020

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.